Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.42 |
| ▸ | RELA | Q04206 | 4/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18216175 | 1.00 | GAA (0.47) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL18208928 | 0.87 | BTK (0.52) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL18208930 | 0.87 | BTK (0.52) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL31500135 | 0.87 | GAA (0.48) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL18208932 | 0.87 | BTK (0.52) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL31008916 | 0.80 | GAA (0.45) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL2771992 | 0.78 | GAA (0.54) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL3621203 | 0.78 | GAA (0.54) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL621675 | 0.76 | BTK (0.54) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL2243640 | 0.76 | BTK (0.54) | GAANFKB1NFKB2RELABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | GAA 503/4885NFKB1 1814/4885NFKB2 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.